Fight against prostate cancerEspagne
Prostate cancer is the second most common cancer in Spanish men. More than 30.000 men are diagnosed with prostate cancer every year in Spain.
Montant total financé €100%Financé
Ticketmaster Clients 6.108€
Les personnes qui ont été naturellement bénéficiées par les actions développées dans le projet.
Les personnes identifiables, qui reçoivent l’effet potentiel des actions menées dans le projet.
- Financement 6.108€
- Total 6.108€
Only men have a prostate gland. The prostate is usually the size and shape of a walnut and grows bigger as you get older. It sits underneath the bladder and surrounds the urethra – the tube men urinate (pee) and ejaculate through.
Prostate cancer can develop when cells in the prostate start to grow in an uncontrolled way. Prostate cancer often grows slowly to start with and may never cause any problems. But some men have prostate cancer that is more likely to spread. This needs treatment to stop it spreading outside the prostate.
The study led by Dr. Anna María Margalef of the Research Institute of the Vall d'Hebron University Hospital (VHIR) consists of studying the possible prognostic value of KIF11 expression in prostate tumors with MYC amplified / overexpressed. In addition, they will explore the therapeutic value of KIF11 in preclinical models and models derived from patients that recapitulate the disease more faithfully (main objective of this proposal).
- Develop new therapeutic treatments for prostate cancer.
- Validate KIF11 as an important therapeutic target for the treatment of hormone-refractory prostate tumors, especially those that present amplification or overexpression of the MYC oncogene.
Qui en bénéficiera ?
Life expectancy of patients and future patients with prostate cancer will be increased.
Objectifs du projet
Increase life expectancy of those affected by prostate cancer.
Asociación Española Contra el Cáncer se conforme pleinement aux 9 principes de transparence et aux bonnes pratiques analysés par la Fondation Lealtad.